CHADS-VASc Score as a Predictor of NoReflow Phenomenon in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

The aim of this work was to evaluate the CHA2DS2-VASc score which is a thromboembolic risk assessment tool recommended in ESC guidelines to be used before starting oral anticoagulant therapy in patients with atrial fibrillation as a simplified applicable tool to predict the no-reflow phenomenon among patients with STEMI who will undergo primary PCI. This prospective study was carried out on patients who were admitted to the PCI capable center with a diagnosis of acute STEMI who were candidates for primary Percutaneous Coronary Intervention. The patients were subdivided into two groups; normal flow group (78 patients) and no reflow group (30 patients). The mean CHA2DS2-VASc scores of both groups were calculated and studied. It revealed that CHA2DS2 VASc score ≥ 2 may be used as a predictor of the no-reflow phenomenon in patients presented with acute ST segment elevation myocardial infarction with a sensitivity of 93.3% and specificity of 74.4%, area under curve: 0.908 with 95% CI (0.829-0.986). So, CHA2DS2 VASc score may be used as a simple and applicable tool to predict no-reflow phenomenon before primary PCI in patients diagnosed with acute ST segment elevation myocardial infarction